PS02.12 Smoking-Related Outcomes of Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy: A Single Institution Study: Topic: Pulmonology by Hafiz, M., Naqash, A.R., Stroud, C.R.G., Bowling, M., Walker, P.R.

Get full text

PS02.12 Smoking-Related Outcomes of Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy: A Single Institution Study by Hafiz, M., Naqash, A.R., Stroud, C.R.G., Bowling, M., Walker, P.R.

Get full text

EP03.01-02 Molecular Characterization of Non-small Cell Lung Cancer in People Living with HIV or Solid Organ Transplants by Aggarwal, V., Xiu, J., Nagasaka, M., Nieva, J., Mekhail, T., Pai, S., Khoury, L.M., Lycan, T., Naqash, A.R., Kareff, S.A., Ocejo, A., Halmos, B., Cheng, H., VanderWalde, A., Borghaei, H., Rodriguez, E., Liu, S., Ma, P., Kim, C.

Get full text

P2.01-29 The Correlation Between K-Ras Mutant Subsets with TP53 Mutation and PD-L1 in Non-Small Cell Lung Cancer (NSCLC) by Karim, N. Abdel, Onuoha, C., Eldesouki, I., Ahmad, I., Mamdani, H., Spira, A., Naqash, A.R.

Get full text

P2.01-100 Spectrum of EGFR Exon 20 Insertion Mutations and Co-Occurring Genetic Alterations in Patients with Non-Small-Cell Lung Cancer by Montenegro, G. Bravo, Nagasaka, M., Ma, P., Naqash, A.R., Mamdani, H., Spira, A., Subramaniam, D., Feldman, R., Kim, C.

Get full text

P1.04-60 Impact of Metastatic Location on Survival in Stage-IV Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy by Naqash, A.R., Jonnalagadda, S., Macherla, S., Polsani, S., Muzaffar, M., Cherry, C., Karim, N. Abdel, Walker, P.

Get full text

OA03.05 Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade: Overall Survival Analysis: Topic: Medical Oncology by Stroud, C.R.G., Hegde, A., Naqash, A.R., Cherry, C., Parent, T., Hardin, J., Walker, P.R.

Get full text

OA03.05 Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade: Overall Survival Analysis by Stroud, C.R.G., Hegde, A., Naqash, A.R., Cherry, C., Parent, T., Hardin, J., Walker, P.R.

Get full text

4A.03 Predictive Utility of c-reactive Protein (CRP) in Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy: Topic: Medical Oncology by Naqash, A.R., Stroud, C.R.G., Cherry, C., Muzaffar, M., Bowling, M., Walker, P.R.

Get full text

4A.03 Predictive Utility of c-reactive Protein (CRP) in Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy by Naqash, A.R., Stroud, C.R.G., Cherry, C., Muzaffar, M., Bowling, M., Walker, P.R.

Get full text

MA16.11 Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI)vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC by Nassar, A.H., Adib, E., Kaldas, D., Feng, J., AbuAli, T., Aredo, J., Fitzgerald, B., Bar, J., Thummalapalli, R., Parikh, K., Whitaker, R., Chen, L., Harris, J., Ayanambakkam, A., Farid, S., Owen, D., Sharp, J., Velazquez, A.I., Ragavan, M., D'aiello, A., Cheng, H., Piotrowska, Z., Wilgucki, M., Reuss, J.E., Patil, T., Nie, Y., Baena Espinar, J., Luders, H., Grohe, C., Sankar, K., Nagasaka, M., Ashara, Y.P., Kwiatkowski, D.J., Mak, R., Amini, A., Lobachov, A., Lin, J.J., Marron, T., Yu, H., Neal, J.W., Wakelee, H.A., Shepherd, F.A., Dilling, T.J., Gray, J.E., Naqash, A.R., Goldberg, S.B., Kim, S.Y.

Get full text

OA03.07 Immune-Related Adverse Events and Clinical Outcome to Anti PD-1 Axis Inhibition in SCLC: A Multicenter Retrospective Analysis by Ricciuti, B., Naqash, A.R., Henick, B., Rangachari, D., Naidoo, J., Venkatraman, D., Lamberti, G., Recondo, G., Zhang, J., Macherla, S., Baig, S., Walker, P., Sehgal, K., Umeton, R., Sholl, L., Rizvi, N., Costa, D., Awad, M.

Get full text